Atlas Trials

Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma

Clinical trial NCT07691450 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07691450
Sponsor
City of Hope Medical Center
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent Anaplastic Large Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular Helper T-Cell LymphomaRecurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeRecurrent Follicular Helper T-Cell Lymphoma, Follicular-TypeRecurrent Follicular Helper T-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Hepatosplenic T-Cell LymphomaRecurrent Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRecurrent Monomorphic Epitheliotropic Intestinal T-cell LymphomaRecurrent Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell LymphomaRecurrent Primary Cutaneous Gamma-Delta T-Cell Lymphoma
Start date
2027-01-03
Primary completion
2029-11-24
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.